Core Insights - Cibus, Inc. announced that two of its disease resistance trait products for canola have been designated as not regulated by USDA-APHIS, allowing unrestricted product development in the U.S. [1][2] Regulatory Developments - The two trait products were developed using Cibus' Rapid Trait Development System™ (RTDS®), enabling targeted genetic changes without recombinant DNA integration, thus not meeting the definition of a "regulated article" [2] - This designation aligns with evolving regulatory frameworks globally, including the EU's recent endorsement of regulations for plants developed by New Genomic Techniques (NGTs) [3] Product Benefits - Cibus' Sclerotinia resistance trait in canola provides multiple modes of action, improving yields and reducing reliance on fungicides, which are essential for controlling Sclerotinia sclerotiorum, a significant pathogen affecting canola and other crops [4] - The disease can reduce canola yields by 7-15%, with losses per infected plant reaching up to 50% [4] Strategic Focus - Cibus aims to extend the application of its traits to other crops like soybean, addressing climate change impacts on plant diseases [5] - The company focuses on developing and licensing gene-edited productivity traits to seed companies, targeting major global row crops such as canola, rice, and soybean [5]

Core Insights - Cibus, Inc. announced that two of its disease resistance trait products for canola have been designated as not regulated by the USDA-APHIS, allowing for unrestricted product development in the U.S. [1][2] Regulatory Developments - The USDA-APHIS confirmed that the products developed using Cibus' Rapid Trait Development System™ (RTDS®) do not meet the definition of a "regulated article," enabling Cibus to advance product development without regulatory restrictions [2][3] - The designation aligns with evolving regulatory frameworks globally, including the EU's recent endorsement of regulations for plants developed by New Genomic Techniques (NGTs), which will treat certain gene-edited products similarly to conventional varieties [3][4] Product Features and Benefits - Cibus' Sclerotinia resistance trait in canola provides multiple modes of action, helping farmers improve yields and reduce reliance on fungicides, which are necessary for controlling Sclerotinia sclerotiorum, a significant pathogen that can reduce canola yields by 7-15% [4][5] - The company anticipates that the application of its traits will extend to other crops like soybean, broadening the benefits of these traits across different agricultural sectors [5] Company Overview - Cibus is a technology company focused on gene editing to develop and license traits to seed companies, addressing productivity and sustainability challenges in agriculture, with an estimated global economic impact of $300 billion annually due to diseases and pests [5] - The company has a pipeline of five productivity traits, including those for weed management in rice and disease resistance, with a long-term focus on major global row crops such as canola, rice, and soybean [5]

Core Insights - Cibus, Inc. is advancing its gene editing technologies and has made significant progress in commercializing herbicide tolerance traits in rice, with interest from markets in Uruguay, Colombia, Brazil, Asia, and the United States [2][3] - The company has established partnerships for disease resistance in canola and oilseed rape, and is making strides in developing multiple modes of action for disease resistance traits [3][7] - Cibus has reported a net loss of $25.8 million for the quarter ended December 31, 2024, a significant decrease from a net loss of $277.2 million in the same period the previous year, primarily due to a prior goodwill impairment [10][12] Regulatory and Market Developments - The California Rice Commission approved Cibus' field research proposal, marking the first authorization for gene-edited rice planting in California [1][8] - The EU is progressing towards finalizing legislation on New Genomic Techniques (NGTs), which could facilitate international trade and improve crop varieties for EU growers [1][8] Financial Performance - Cibus reported revenue of $1.2 million for the quarter ended December 31, 2024, compared to $1.1 million in the same quarter of 2023 [10][26] - Research and development expenses decreased to $12.4 million from $14.2 million year-over-year, reflecting cost-saving measures [12][26] - The company had cash and cash equivalents of $14.4 million as of December 31, 2024, down from $32.7 million in the previous year [12][29] Strategic Initiatives - Cibus is focused on expanding its partnerships with rice seed companies across North and South America, with plans for initial trait validation trials in Latin America [9] - The company aims to achieve $10 million in annual cost savings through strategic realignment and facility consolidation [9] - Cibus is developing a fully operational soybean platform, with expectations for HT2 trait edits in soybean plants in 2025 [9][12]

Core Insights - Cibus has announced promising results from its third mode of action for Sclerotinia resistance in canola, which is expected to enhance crop yields and reduce fungicide usage for farmers [1][4] - The company's Rapid Trait Development System™ (RTDS) allows for efficient gene editing and development of plant traits that are indistinguishable from conventional breeding [2][7] - Cibus has completed edits in four modes of action for Sclerotinia resistance and anticipates completing field tests by the end of 2025 [3] Company Overview - Cibus is a technology company focused on gene editing to develop and license traits to seed companies, addressing productivity and sustainability challenges in agriculture [6][7] - The company is not a seed company but aims to improve productivity traits for major global crops such as canola, rice, and soybean [7] - Cibus has a pipeline of five productivity traits, including Sclerotinia resistance, which is a near-term focus [7] Industry Context - Sclerotinia sclerotiorum is a significant fungal pathogen affecting canola and other crops, causing yield losses of 7-15% and potentially up to 90% in severe cases [5] - The economic impact of diseases and pests in agriculture is estimated to cost the global economy approximately $300 billion annually [6][7] - The development of durable resistance traits is crucial as climate change affects the prevalence and distribution of crop diseases [4][5]